Trinity Biotech (NASDAQ:TRIB) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report issued on Monday. The firm set a “sell” rating on the stock.

Trinity Biotech Stock Performance

Shares of TRIB stock opened at $0.52 on Monday. Trinity Biotech has a 52 week low of $0.48 and a 52 week high of $3.55. The stock has a market capitalization of $9.39 million, a PE ratio of -0.23 and a beta of 1.21. The stock’s fifty day moving average is $0.72 and its 200-day moving average is $1.04.

Hedge Funds Weigh In On Trinity Biotech

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its stake in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent quarter. 78.97% of the stock is currently owned by institutional investors.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.